Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Mar 15, 2014 4:47pm

101 Views

Post# 22327954

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Zenith

Hi Sanfran.

Thanks for the perspective. It is very re-assuring and I am feeling as you expressed in your last paragraph. A very pleasant shift in attitude for me from the past few weeks.

This bodes well for RVX and Zenith.
Cheers
Toinv

Bullboard Posts

Canadian rare earths stock up as drilling starts at uranium property